Skip to main content
SpringerLink
Log in

Thalidomide in Cutaneous Lupus Erythematosus

  • Chapter
Cutaneous Lupus Erythematosus

  • 878 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aronson IK, Yu R, West DP, van den Broek H, Antel J (1984) Thalidomide induced peripheral neuropathy. Arch Dermatol 120:1466–1470

    Article  PubMed  Google Scholar 

  • Atra E, Sato EI (1993) Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 11:487–493

    Google Scholar 

  • Barnhill RL, Doll NJ, Millikan LE, Hastings RC (1984) Studies on the anti-inflammatory properties of thalidomide: effects on polymorphonuclear leukocytes and monocytes. J Am Acad Dermatol 11:814–819

    PubMed  Google Scholar 

  • Belmont HM, Buyon J, Giorno R, Abramson S (1994) Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum 37:376–383

    PubMed  Google Scholar 

  • Clemmensen OJ, Olsen PZ, Andersen KE (1984) Thalidomide neurotoxicity. Arch Dermatol 120:338–341

    Article  PubMed  Google Scholar 

  • Corral LG, Kaplan G (1999) Immunomodulationby thalidomide and thalidomide analogues. Ann Rheum Dis 58(Suppl I):I107–113

    PubMed  Google Scholar 

  • D’Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitorof angiogenesis. Proc Natl Acad Sci USA 91:4082–4085

    PubMed  Google Scholar 

  • de Iongh RU (1990) A quantitative ultrastructural study of motor and sensory lumbosacral nerve roots in the thalidomide-treated rabbit fetus. J Neuropathol Exp Neurol 49:564–581

    PubMed  Google Scholar 

  • Dean GS, Tyrell-Price J, Crawley E, Isenberg DA (2000) Cytokines and systemic lupus erythematosus. Ann Rheum Dis 59:243–251

    Article  PubMed  Google Scholar 

  • Duong DJ, Spigel GT, Moxley TR 3rd, Gaspari AA (1999) American experiencewith low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch Dermatol 135:1079–1087

    Article  PubMed  Google Scholar 

  • Faure M, Thivolet J, Gaucherand M(1980) Inhibition of PMN leukocytes chemotaxis by thalidomide. Arch Dermatol Res 269:275–280

    Article  PubMed  Google Scholar 

  • Flageul B, Wallach D, Cavalier-Balloy B, Bachelez H, Carsuzaa F, Dubertret L (2000) Thalidomide and thrombosis. Ann Dermatol Venereol127:171–174

    PubMed  Google Scholar 

  • Frances C, El Khoury S, Gompler A, Becherel PA, Chosidow O, Piette JC (2002) Transient secondary amenorrhea in women treated by thalidomide. Eur J Dermatol 12:63–65

    PubMed  Google Scholar 

  • Fullerton PM, O’Sullivan DJ (1968) Thalidomide neuropathy: a clinical, electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatric 31:543–551

    Google Scholar 

  • Gad SM, Shannon EJ, Krotoski WA, Hastings RC (1985) Thalidomide induces imbalances in Tlymphocyte sub-populations in the circulating blood of healthy males. Lepr Rev 56:35–39

    PubMed  Google Scholar 

  • Gardner-Medwin JM, Smith NJ, Powell RJ(1994) Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet’s disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 53:828–832

    PubMed  Google Scholar 

  • Geitz H, Handt S, Zwingenberger K(1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesionca scade. Immunopharmacology 31:213–221

    Article  PubMed  Google Scholar 

  • Gompel A, Frances C, Piette JC, Blanc AS, Cordoliani F, Piette AM (1999) Ovarian failure with thalidomide treatment in complex aphthosis: commenton the concise communicationby Ordi et al. Arthritis Rheum 42:2259–2260

    Article  PubMed  Google Scholar 

  • Gutiérrez-Rodriguez O, Starusta-Bacal P, Gutiérrez-Montes O (1989) Treatment of rheumatoid arthritis: the thalidomide experience. J Rheumatol 16:158–163

    PubMed  Google Scholar 

  • Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H (1998) Thalidomide in the treatment of the mucocutaneous lesions of Behcet’s syndrome. A randomised, double-blind, placebo controlled trial. Ann Intern Med 128:443–459

    PubMed  Google Scholar 

  • Haslett PA, Corral LG, Albert M, Kaplan G(1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187:1885–1892

    Article  PubMed  Google Scholar 

  • Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtando R, Avalos-Diaz E (1998) Renal expression of IL-6 and TNF alpha genes in lupus nephritis. Lupus 7:154–158

    Article  PubMed  Google Scholar 

  • Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO (1990) Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 87:1233–1237

    PubMed  Google Scholar 

  • Jones SM, Mathew CM, Dixey J, Lovell CR, McHugh NJ (1996) VCAM-1 expression on en dothelium in lesions from cutaneous lupus erythematosus is increased compared with systemic and localized scleroderma. Br J Dermatol 135:678–686

    PubMed  Google Scholar 

  • Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr (2001) Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem 276:22382–22387

    Article  PubMed  Google Scholar 

  • Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, Macher E (1983) Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 108:461–466

    PubMed  Google Scholar 

  • Kohchiyama A, Oka D, Ueki H (1985) T-cell subsets in lesions of systemic and discoid lupus erythematosus. J Cutan Pathol 12:493–499

    PubMed  Google Scholar 

  • Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE (1998) Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 236:461–466

    Article  PubMed  Google Scholar 

  • Kyriakis KP, Kontochristopoulos GJ, Panteleos DN (2000) Experiencewith low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol 39:218–222

    Article  PubMed  Google Scholar 

  • Lagueny A, Rommel A, Vignolly B, Taieb A, Vendeaud-Busquet M, Doutre MS, Julien J(1986) Thalidomide neuropathy: an electrophysiologic study. Muscle Nerve 9:837–844

    Article  PubMed  Google Scholar 

  • Lee SH, Park SH, Min JK, Kim SI, Yoo WH, Hong YS, Park JH, Cho CS, Kim TG, Han H, Kim HY (1997) Decreased tumour necrosis factor-beta production in TNFB⋆2 homozygote: an important predisposing factor of lupus nephritis in Koreans. Lupus 6:603–609

    PubMed  Google Scholar 

  • McHugh SM, Rifkin IR, Deighton J Wilson AB, Lachmann PJ, Lockwood CM, Ewan PW (1995) The immunosuppressive drug thalidomide induces T helper type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 99:160–167

    PubMed  Google Scholar 

  • Mellin GW, Katzenstein M(1962) The saga of thalidomide: neuropathy to embryopathy, with case reports and congenital abnormalities. N Engl J Med 23:1184–1190

    Google Scholar 

  • Mellin GW (1962) The saga of thalidomide (concluded). N Engl J Med. 267:1238–1244

    PubMed  Google Scholar 

  • Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor α productionby enhancingm RNA degradation. J Exp Med 177:1675–1680

    Article  PubMed  Google Scholar 

  • Moreira AL, Friedlander DR, Shif B, Kaplan G, Zagzag D (1999) Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol 43:109–114

    PubMed  Google Scholar 

  • Ochonisky S, Verroust J, Bastuji-Garin S, Gherardi R, Revuz J (1994) Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 130:66–69

    Article  PubMed  Google Scholar 

  • Ordi-Ros J, Cortes F, Martinez N, Mauri M, de Torres I, Vilardell M(1998) Thalidomide induces amenorrhea in patients with lupus disease. Arthritis Rheum 41:2273–2275

    Article  PubMed  Google Scholar 

  • Ordi-Ros J, Cortes F, Cucurull E, Mauri M, Bujan S, Vilardell M(2000) Thalidomide in the treatmentof cutaneous lupus refractory to conventional therapy. J Rheumatol 27:1429–1433

    PubMed  Google Scholar 

  • Osman K, Comenzo R, Rajkumar SV (2001) Deep vein thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344:1951–1952

    Article  PubMed  Google Scholar 

  • Passeron T, Lacour JP, Murr D, Ortonne JP (2001) Thalidomide-induced amenorrhea: two cases. Br J Dermatol 144:1262–1295

    Article  PubMed  Google Scholar 

  • Powell RJ, Gardner-Medwin JM (1994) Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 70:901–904

    PubMed  Google Scholar 

  • Randall T (1990) Thalidomide has 37-year history. JAMA 263:1474

    Google Scholar 

  • Rao DG, Kane NM, Oware A (2000) Thalidomide neuropathy: role of F-wave monitoring. Muscle Nerve 23:1301–1302

    Article  PubMed  Google Scholar 

  • Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ, Ruiz-Palacios GM (1996) Effects of thalidomide on HIV-associated wasting syndrome: a randomised, double-blind, placebo-controlled clinical trial. AIDS 10:1501–1507

    PubMed  Google Scholar 

  • Rovelli A, Amigo C, Nesi F, Balduzzi A, Nicolini B, Locasciulli A, Vassallo E, Miniero R, Uderzo C (1998) The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation. Bone Marrow Transplant 21:577–581

    Article  PubMed  Google Scholar 

  • Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 173:699–703

    Article  PubMed  Google Scholar 

  • Sato EI, Assis LS, Lorenzi VP, Andrade LE (1998) Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev Assoc Med Bras 44:289–293

    Article  PubMed  Google Scholar 

  • Settles B, Stevenson A, Wilson K, Mack C, Ezell T, Davis MF, Taylor LD (2001) Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide. Cell Mol Biol (Noisy-le-grand) 47:1105–1114

    Google Scholar 

  • Shannon EJ, Miranda RO, Morales MJ, Hastings RC (1981) Inhibition of de novo IgM antibody synthesis by thalidomide as a relevant mechanism of action in leprosy. Scand J Immunol 13:553–562

    PubMed  Google Scholar 

  • Sheskin J (1965) Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6:303–306

    Google Scholar 

  • Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565–1571

    Article  PubMed  Google Scholar 

  • Stevens RJ, Andujar C, Edwards CJ, Ames PRJ, Barwick AR, Khamashta MA, Hughes GRV (1997) Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 36:353–359

    Article  PubMed  Google Scholar 

  • Tseng S, Pak G, Washenik K, Pomeranz MK, Shupack JL (1996) Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 35:969–979

    Article  PubMed  Google Scholar 

  • Vogelsang GB (1993) Acuteand chronic graft-versus-host disease. Curr Opin Oncol 5:276–281

    PubMed  Google Scholar 

  • Walchner M, Messer G, Wierenga EA (1995) Reconstitution oftr anscription factorbinding to the conserved lymphokine element-o and downregulation of NF-kB activity after thalidomide treatment of systemic lupus erythematosus. Arch Dermatol Res 287:347

    Google Scholar 

  • Walchner M, Meurer M, Plewig G, Messer G (2000) Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol 39:383–388

    Article  PubMed  Google Scholar 

  • Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J (1998) Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 352:1586–1589

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Yousuf Karim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria J. Cuadrado
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hautklinik, Universitätsklinikum Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany

    Annegret Kuhn  & Thomas Ruzicka  & 

  2. HELIOS Klinikum Wuppertal Klinik für Dermatologie, Allergologie und Umweltmedizin, Universitätsklinikum Witten-Herdecke, Arrenbergerstraße 20, 42117, Wuppertal, Germany

    Percy Lehmann

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin · Heidelberg

About this chapter

Cite this chapter

Karim, Y., Cuadrado, M.J. (2005). Thalidomide in Cutaneous Lupus Erythematosus. In: Kuhn, A., Lehmann, P., Ruzicka, T. (eds) Cutaneous Lupus Erythematosus. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26581-3_28

Download citation

  • DOI: https://doi.org/10.1007/3-540-26581-3_28

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-44266-0

  • Online ISBN: 978-3-540-26581-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation